BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37270540)

  • 1. Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding.
    Faber EB; Sun L; Tang J; Roberts E; Ganeshkumar S; Wang N; Rasmussen D; Majumdar A; Hirsch LE; John K; Yang A; Khalid H; Hawkinson JE; Levinson NM; Chennathukuzhi V; Harki DA; Schönbrunn E; Georg GI
    Nat Commun; 2023 Jun; 14(1):3213. PubMed ID: 37270540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice.
    Faber EB; Wang N; John K; Sun L; Wong HL; Burban D; Francis R; Tian D; Hong KH; Yang A; Wang L; Elsaid M; Khalid H; Levinson NM; Schönbrunn E; Hawkinson JE; Georg GI
    J Med Chem; 2023 Feb; 66(3):1928-1940. PubMed ID: 36701569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
    Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
    Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.
    Faber EB; Tian D; Burban D; Levinson NM; Hawkinson JE; Georg GI
    ACS Chem Biol; 2020 Jul; 15(7):1759-1764. PubMed ID: 32433863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Conformational Activation of CDK2 Kinase.
    Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
    Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II Inhibitors Targeting CDK2.
    Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
    ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.
    Coxon CR; Anscombe E; Harnor SJ; Martin MP; Carbain B; Golding BT; Hardcastle IR; Harlow LK; Korolchuk S; Matheson CJ; Newell DR; Noble ME; Sivaprakasam M; Tudhope SJ; Turner DM; Wang LZ; Wedge SR; Wong C; Griffin RJ; Endicott JA; Cano C
    J Med Chem; 2017 Mar; 60(5):1746-1767. PubMed ID: 28005359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
    Talapati SR; Goyal M; Nataraj V; Pothuganti M; R SM; Gore S; Ramachandra M; Antony T; More SS; Rao NK
    Chem Biol Drug Des; 2021 Nov; 98(5):857-868. PubMed ID: 34423559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
    Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allostery governs Cdk2 activation and differential recognition of CDK inhibitors.
    Majumdar A; Burban DJ; Muretta JM; Thompson AR; Engel TA; Rasmussen DM; Subrahmanian MV; Veglia G; Thomas DD; Levinson NM
    Nat Chem Biol; 2021 Apr; 17(4):456-464. PubMed ID: 33526892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydroindazole inhibitors of CDK2/cyclin complexes.
    Lee JC; Hong KH; Becker A; Tash JS; Schönbrunn E; Georg GI
    Eur J Med Chem; 2021 Mar; 214():113232. PubMed ID: 33550184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of CDK2 and CDK5 Dual Degrader TMX-2172.
    Teng M; Jiang J; He Z; Kwiatkowski NP; Donovan KA; Mills CE; Victor C; Hatcher JM; Fischer ES; Sorger PK; Zhang T; Gray NS
    Angew Chem Int Ed Engl; 2020 Aug; 59(33):13865-13870. PubMed ID: 32415712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
    Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
    Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Activity Relationships of Hexahydrocyclopenta[c]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR.
    Carlino L; Christodoulou MS; Restelli V; Caporuscio F; Foschi F; Semrau MS; Costanzi E; Tinivella A; Pinzi L; Lo Presti L; Battistutta R; Storici P; Broggini M; Passarella D; Rastelli G
    ChemMedChem; 2018 Dec; 13(24):2627-2634. PubMed ID: 30457710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.
    Johnson LN; De Moliner E; Brown NR; Song H; Barford D; Endicott JA; Noble ME
    Pharmacol Ther; 2002; 93(2-3):113-24. PubMed ID: 12191604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception†.
    Faber EB; Wang N; Georg GI
    Biol Reprod; 2020 Aug; 103(2):357-367. PubMed ID: 32543655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
    Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
    Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.